Positions

Overview

  • Dr. Roberson is a neurologist and neuroscientist whose research is focused on age-related neurodegenerative disorders. He received his A.B. with highest honors from Princeton University, then earned his Ph.D in neuroscience and M.D. with high honors at Baylor College of Medicine where he studied molecular mechanisms of learning and memory. He completed a residency in neurology at the University of California San Francisco, where he also served as Chief Resident in Neurology. After residency, he completed a clinical fellowship in behavioral neurology at UCSF and resumed basic research at the Gladstone Institute of Neurological Disease. He joined the faculty at UAB in 2008.

    Dr. Roberson's laboratory investigates mechanisms and therapeutic approaches to Alzheimer's disease and frontotemporal dementia, and he directs the Center for Neurodegeneration and Experimental Therapeutics. He is also active in clinical research and patient care. He directs the UAB Alzheimer’s Disease Center, leads clinical trials, and cares for patients with memory disorders and dementia at the Kirklin Clinic.
  • Selected Publications

    Book

    Year Title Altmetric
    2017 Clinical Neuroscience 2017
    2011 Alzheimer's Disease and Frontotemporal Dementia 2011

    Chapter

    Year Title Altmetric
    2017 Frontotemporal Dementia.  141-175. 2017
    2016 Animal models of dementia.  77-93. 2016
    2011 Preface 2011
    2009 Animal models of dementia.  131-141. 2009
    2007 Molecular aspects of memory dysfunction in Alzheimer’s disease.  245-293. 2007

    Research Overview

  • Alzheimer's disease, frontotemporal dementia, and related disorders
  • Principal Investigator On

  • The Progranulin C-Terminal Domain and AAV-Progranulin Gene Therapy for Frontotemporal Dementia  awarded by National Institute on Aging/NIH/DHHS 2020 - 2024
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core  awarded by MAYO CLINIC 2019 - 2024
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core  awarded by MAYO CLINIC 2019 - 2024
  • UAB Alzheimer's Disease Research Center  awarded by National Institute on Aging/NIH/DHHS 2020 - 2023
  • BIN1, Interneuron Activity, and Network Dysfunction in Alzheimer Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2022
  • Tau-Fyn Interaction and Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2020 - 2022
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).  awarded by Washington University 2018 - 2022
  • Toward Therapeutic Approaches to TREM2-R47H in Alzheimer's Disease  awarded by Alzheimer's Drug Discovery Foundation 2019 - 2022
  • Optimizing Progranulin Gene Therapy for Frontotemporal Dementia  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2020 - 2021
  • Circadian Changes in Network Excitability and Alzheimer Disease Pathogenesis  awarded by National Institute on Aging/NIH/DHHS 2019 - 2021
  • Validation of Online Methods to Predict and Monitor Cognitive Decline  awarded by University of California, San Francisco 2018 - 2021
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”)  awarded by THE WASHINGTON UNIVERSITY 2018 - 2021
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017 - 2020
  • Private Grant  awarded by BIOGEN IDEC, INC. 2017 - 2020
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Private Grant  awarded by AVID RADIOPHARMACEUTICALS 2014 - 2018
  • Developing Inhibitors Of Tau-SH3 Interactions As Treatments For Alzheimer's Disease And Hyperexcitability  awarded by WESTON BRAIN INSTITUTE 2017 - 2018
  • Private Grant  awarded by ALECTOR, INC. 2016 - 2018
  • Development of Inhibitors of the Tau-Fyn Interaction For the Treatment of Alzheimer's Disease  awarded by BRIGHT FOCUS FOUNDATION 2015 - 2018
  • Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study  awarded by American College of Radiology 2016 - 2018
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency (Consortium for Frontotemporal Dementia Research)  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017
  • Consortium for Frontotemporal Dementia Research  awarded by University of California, San Francisco 2008 - 2017
  • BIN1 and Tau Interactions Regulating Neuronal Calcium  awarded by Alzheimer's Association 2014 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • Investigating the Impact of Cognition on Functional Ability in PSP  awarded by CUREPSP 2015 - 2017
  • Mechanisms for the Benefit of Tau Reduction in Alzheimer Disease Models  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2017
  • Targeting the Tau-Fyn Interaction in Alzheimer's Disease  awarded by WESTON BRAIN INSTITUTE 2016 - 2017
  • Private Grant  awarded by C2N DIAGNOSTICS, LLC 2015 - 2016
  • Mechanisms of Frontotemporal Dementia Like Behavior in Progranulin Deficient Mice  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2016
  • Weston Advisor Fellowship  awarded by WESTON BRAIN INSTITUTE 2015 - 2016
  • Tau and Glutamatergic Synapses in Frontotemporal Dementia  awarded by National Institute on Aging/NIH/DHHS 2013 - 2016
  • Molecular Mechanisms of Aging-Related Neuronal Dysfunction in Progranulin-Insufficient Mice  awarded by American Federation for Aging Research 2014 - 2015
  • Epileptiform Activity in Neurodegenerative Disease  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2014
  • Characterizing an Inducible Model for the Protective Effects of Tau Reduction  awarded by American Health Assistance Foundation 2010 - 2013
  • Private Grant  awarded by ALLON THERAPEUTICS 2010 - 2013
  • Tau and Fyn in Alzheimer's Disease Pathogenesis  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2012
  • The Role of Tau in Neurodegeneration  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2012
  • Mechanisms for Tau Involvement in Alzheimer's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2012
  • Investigator On

  • Consequences of Noradrenergic Degeneration in the Novel TgF344-AD Rat Model  awarded by National Institute on Aging/NIH/DHHS 2020 - 2025
  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS 2020 - 2025
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2024
  • Identifying Therapeutic Targets That Confer Synaptic Resilience to Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • Circadian Dysfunction and Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2022
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2022
  • UAB Training Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Targeting Rho Kinases for Alzheimer's Disease Therapeutics  awarded by National Institute on Aging/NIH/DHHS 2017 - 2022
  • Alpha-Synuclein Aggregate Induced Synapse Loss is a Pathological Event contributing to Lewy Body Dementias  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2020 - 2021
  • Day-Night Differences in Hippocampal Neurophysiology in Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2020 - 2021
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2021
  • Private Grant  awarded by EISAI, INC. 2013 - 2021
  • Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People with Alzheimer Dementia and Traumatic Brain Injury  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2021
  • Global Alzheimer’s Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease  awarded by University of Southern California 2019 - 2021
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study  awarded by University of Southern California 2019 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by ABBVIE INC 2018 - 2020
  • Private Grant  awarded by ABBVIE INC 2017 - 2020
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2015 - 2019
  • Private Grant  awarded by NEURIM PHARMACEUTICALS 2017 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Reducing Tau as a Therapeutic Strategy for Improving Cognitive Dysfunction in Parkinson's Disease  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2019
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016 - 2018
  • Circadian Dysfunction and GSK3 in Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2018
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC. 2016 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Functional Change in Mild Cognitive Impairment  awarded by National Institute on Aging/NIH/DHHS 2010 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study: A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2015 - 2016
  • Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)  awarded by University of Southern California 2015 - 2016
  • Alzehimer's Disease Neuroimaging Initiative (ADNI)  awarded by University of California, San Diego 2005 - 2016
  • Training Program in the Neurobiology of Cognition and Cognitive Disorders  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - The LEARN Study A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of California, San Diego 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Preclinical Test for the Efficacy of Adrenergic Agents in Treatment of AD  awarded by National Institute on Aging/NIH/DHHS 2012 - 2015
  • A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-To-Moderate Alzheimer's Disease  awarded by University of California, San Diego 2010 - 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2013
  • Amyloid Imaging, VMCI, and Analysis for ADNI  awarded by University of California, San Diego 2009 - 2012
  • Education And Training

  • Doctor of Medicine, Baylor College of Medicine 1999
  • Doctor of Philosophy in Neuroscience, Baylor College of Medicine 1997
  • Baylor College of Medicine, Internship 2000
  • UCSF Medical Center Neurology, Residency 2003
  • UCSF Medical Center, Postdoctoral Fellowship 2005
  • Full Name

  • Erik Roberson